palbociclib (cdk4 Search Results


cdk4 inhibitor palbociclib pd-0332991 sel-s1116-5mg  (Biozol Diagnostica Vertrieb GmbH)
90
Biozol Diagnostica Vertrieb GmbH cdk4 inhibitor palbociclib pd-0332991 sel-s1116-5mg
( A ) Gene expression levels of 4 cyclin-dependent kinases (CDK1, CDK2, <t>CDK4</t> and CDK6) are analyzed for each of the 3 identified main groups. Data are given as standard box plots. CDK2 and CDK4 are consistently highly expressed in all groups. Positions of each CDK gene are shown on the mean SOM expression landscape indicated by arrows. ( B ) Growth inhibition curves are shown for treatments of a patient-derived melanoma short-term culture using inhibitors directed against CDK2 (purvanolol), CDK4 <t>palbociclib,</t> activated BRAF (vemurafenib), ERK1/2 (SCH772984), and MEK1/2 (cobimetinib).
Cdk4 Inhibitor Palbociclib Pd 0332991 Sel S1116 5mg, supplied by Biozol Diagnostica Vertrieb GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/palbociclib+(cdk4/cdk4+inhibitor+palbociclib+pd+0332991+sel+s1116+5mg/pmc05352202-231-7-12
Average 90 stars, based on 1 article reviews
cdk4 inhibitor palbociclib pd-0332991 sel-s1116-5mg - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
cdk4/6 inhibitor palbociclib  (KU Leuven)
90
KU Leuven cdk4/6 inhibitor palbociclib
( A ) Gene expression levels of 4 cyclin-dependent kinases (CDK1, CDK2, <t>CDK4</t> and CDK6) are analyzed for each of the 3 identified main groups. Data are given as standard box plots. CDK2 and CDK4 are consistently highly expressed in all groups. Positions of each CDK gene are shown on the mean SOM expression landscape indicated by arrows. ( B ) Growth inhibition curves are shown for treatments of a patient-derived melanoma short-term culture using inhibitors directed against CDK2 (purvanolol), CDK4 <t>palbociclib,</t> activated BRAF (vemurafenib), ERK1/2 (SCH772984), and MEK1/2 (cobimetinib).
Cdk4/6 Inhibitor Palbociclib, supplied by KU Leuven, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/palbociclib+(cdk4/cdk4+6+inhibitor+palbociclib/pm35784555-7-17-82
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitor palbociclib - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
cdk4/6 inhibitor palbociclib  (Absource Diagnostics GmbH)
90
Absource Diagnostics GmbH cdk4/6 inhibitor palbociclib
( A ) Gene expression levels of 4 cyclin-dependent kinases (CDK1, CDK2, <t>CDK4</t> and CDK6) are analyzed for each of the 3 identified main groups. Data are given as standard box plots. CDK2 and CDK4 are consistently highly expressed in all groups. Positions of each CDK gene are shown on the mean SOM expression landscape indicated by arrows. ( B ) Growth inhibition curves are shown for treatments of a patient-derived melanoma short-term culture using inhibitors directed against CDK2 (purvanolol), CDK4 <t>palbociclib,</t> activated BRAF (vemurafenib), ERK1/2 (SCH772984), and MEK1/2 (cobimetinib).
Cdk4/6 Inhibitor Palbociclib, supplied by Absource Diagnostics GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/palbociclib+(cdk4/cdk4+6+inhibitor+palbociclib/bio_rxiv__2024__01__26__577389-237-24-42
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitor palbociclib - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
cdk4/6 inhibitor palbociclib  (ClinTrials BioResearch)
90
ClinTrials BioResearch cdk4/6 inhibitor palbociclib
( A ) Gene expression levels of 4 cyclin-dependent kinases (CDK1, CDK2, <t>CDK4</t> and CDK6) are analyzed for each of the 3 identified main groups. Data are given as standard box plots. CDK2 and CDK4 are consistently highly expressed in all groups. Positions of each CDK gene are shown on the mean SOM expression landscape indicated by arrows. ( B ) Growth inhibition curves are shown for treatments of a patient-derived melanoma short-term culture using inhibitors directed against CDK2 (purvanolol), CDK4 <t>palbociclib,</t> activated BRAF (vemurafenib), ERK1/2 (SCH772984), and MEK1/2 (cobimetinib).
Cdk4/6 Inhibitor Palbociclib, supplied by ClinTrials BioResearch, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/palbociclib+(cdk4/cdk4+6+inhibitor+palbociclib/pmc09893357-72-13-4
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitor palbociclib - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
cdk4 6 inhibitor palbociclib  (Merck & Co)
86
Merck & Co cdk4 6 inhibitor palbociclib
(A) Experimental setup for steady-state RNA sequencing. (B) Numbers of up- or downregulated genes (log2-fold change >1) after 24 or 48 h HRAS G12V or KRAS G12V induction. (C) Numbers of unique and shared up-regulated genes after HRAS G12V or KRAS G12V induction. (D) Functional enrichment analysis (gene ontology, biological process) of genes downregulated 48 h after HRAS G12V or KRAS G12V induction. (E) Functional enrichment analysis (gene ontology, biological process) of genes upregulated 48 h after HRAS G12V or KRAS G12V induction. (G) Log2 fold-change in hallmark E2F target gene expression after HRAS G12V or KRAS G12V induction. (H) E2F1 expression (RNAseq, DEseq2) after HRAS G12V or KRAS G12V induction. N=3. (I) Log2 fold-change in hallmark MYC target gene expression after HRAS G12V or KRAS G12V induction. (J) MYC expression (RNAseq, DEseq2) after HRAS G12V or KRAS G12V induction. N=3. (K) Protein levels of pRB1 and α-TUBULIN after oncogene induction for the times indicated. (L) S phase percentage after HRAS G12V induction as determined by EdU labelling and flow cytometry. N=4. (M) S phase percentage after KRAS G12V induction. N=4. (N) S phase percentage after BRAF V600E induction. N=4. (O) Experimental setup <t>for</t> <t>CDK4/6</t> inhibitor (CDK4/6i) treatment and release. (P) S phase percentage after HRAS G12V induction and treatment with CDK4/6i. N=2. (Q) Nuclear EU intensity after HRAS G12V induction and release from CDK4/6i. N=3. (R) Average replication fork speeds after HRAS G12V induction and release from CDK4/6i. N=3. Means +/-SEM (bars) are shown with 2-way ANOVA or mixed effects analysis.
Cdk4 6 Inhibitor Palbociclib, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/palbociclib+(cdk4/6+cdk4+inhibitor+palbociclib/bio_rxiv__64898__2026__03__16__711577-193-15-23
Average 86 stars, based on 1 article reviews
cdk4 6 inhibitor palbociclib - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier
cdk4/6 inhibitors palbociclib  (TranScrip Partners)
90
TranScrip Partners cdk4/6 inhibitors palbociclib
(A) Experimental setup for steady-state RNA sequencing. (B) Numbers of up- or downregulated genes (log2-fold change >1) after 24 or 48 h HRAS G12V or KRAS G12V induction. (C) Numbers of unique and shared up-regulated genes after HRAS G12V or KRAS G12V induction. (D) Functional enrichment analysis (gene ontology, biological process) of genes downregulated 48 h after HRAS G12V or KRAS G12V induction. (E) Functional enrichment analysis (gene ontology, biological process) of genes upregulated 48 h after HRAS G12V or KRAS G12V induction. (G) Log2 fold-change in hallmark E2F target gene expression after HRAS G12V or KRAS G12V induction. (H) E2F1 expression (RNAseq, DEseq2) after HRAS G12V or KRAS G12V induction. N=3. (I) Log2 fold-change in hallmark MYC target gene expression after HRAS G12V or KRAS G12V induction. (J) MYC expression (RNAseq, DEseq2) after HRAS G12V or KRAS G12V induction. N=3. (K) Protein levels of pRB1 and α-TUBULIN after oncogene induction for the times indicated. (L) S phase percentage after HRAS G12V induction as determined by EdU labelling and flow cytometry. N=4. (M) S phase percentage after KRAS G12V induction. N=4. (N) S phase percentage after BRAF V600E induction. N=4. (O) Experimental setup <t>for</t> <t>CDK4/6</t> inhibitor (CDK4/6i) treatment and release. (P) S phase percentage after HRAS G12V induction and treatment with CDK4/6i. N=2. (Q) Nuclear EU intensity after HRAS G12V induction and release from CDK4/6i. N=3. (R) Average replication fork speeds after HRAS G12V induction and release from CDK4/6i. N=3. Means +/-SEM (bars) are shown with 2-way ANOVA or mixed effects analysis.
Cdk4/6 Inhibitors Palbociclib, supplied by TranScrip Partners, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/palbociclib+(cdk4/cdk4+6+inhibitors+palbociclib/pm35347591-47-109-19
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitors palbociclib - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
palbociclib (cdk4/6-inhibitor)  (Georg Thieme Verlag KG)
90
Georg Thieme Verlag KG palbociclib (cdk4/6-inhibitor)
(A) Experimental setup for steady-state RNA sequencing. (B) Numbers of up- or downregulated genes (log2-fold change >1) after 24 or 48 h HRAS G12V or KRAS G12V induction. (C) Numbers of unique and shared up-regulated genes after HRAS G12V or KRAS G12V induction. (D) Functional enrichment analysis (gene ontology, biological process) of genes downregulated 48 h after HRAS G12V or KRAS G12V induction. (E) Functional enrichment analysis (gene ontology, biological process) of genes upregulated 48 h after HRAS G12V or KRAS G12V induction. (G) Log2 fold-change in hallmark E2F target gene expression after HRAS G12V or KRAS G12V induction. (H) E2F1 expression (RNAseq, DEseq2) after HRAS G12V or KRAS G12V induction. N=3. (I) Log2 fold-change in hallmark MYC target gene expression after HRAS G12V or KRAS G12V induction. (J) MYC expression (RNAseq, DEseq2) after HRAS G12V or KRAS G12V induction. N=3. (K) Protein levels of pRB1 and α-TUBULIN after oncogene induction for the times indicated. (L) S phase percentage after HRAS G12V induction as determined by EdU labelling and flow cytometry. N=4. (M) S phase percentage after KRAS G12V induction. N=4. (N) S phase percentage after BRAF V600E induction. N=4. (O) Experimental setup <t>for</t> <t>CDK4/6</t> inhibitor (CDK4/6i) treatment and release. (P) S phase percentage after HRAS G12V induction and treatment with CDK4/6i. N=2. (Q) Nuclear EU intensity after HRAS G12V induction and release from CDK4/6i. N=3. (R) Average replication fork speeds after HRAS G12V induction and release from CDK4/6i. N=3. Means +/-SEM (bars) are shown with 2-way ANOVA or mixed effects analysis.
Palbociclib (Cdk4/6 Inhibitor), supplied by Georg Thieme Verlag KG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/palbociclib+(cdk4/palbociclib++cdk4+6+inhibitor+/pm33291179-62-23-14
Average 90 stars, based on 1 article reviews
palbociclib (cdk4/6-inhibitor) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


( A ) Gene expression levels of 4 cyclin-dependent kinases (CDK1, CDK2, CDK4 and CDK6) are analyzed for each of the 3 identified main groups. Data are given as standard box plots. CDK2 and CDK4 are consistently highly expressed in all groups. Positions of each CDK gene are shown on the mean SOM expression landscape indicated by arrows. ( B ) Growth inhibition curves are shown for treatments of a patient-derived melanoma short-term culture using inhibitors directed against CDK2 (purvanolol), CDK4 palbociclib, activated BRAF (vemurafenib), ERK1/2 (SCH772984), and MEK1/2 (cobimetinib).

Journal: Oncotarget

Article Title: Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq

doi: 10.18632/oncotarget.13666

Figure Lengend Snippet: ( A ) Gene expression levels of 4 cyclin-dependent kinases (CDK1, CDK2, CDK4 and CDK6) are analyzed for each of the 3 identified main groups. Data are given as standard box plots. CDK2 and CDK4 are consistently highly expressed in all groups. Positions of each CDK gene are shown on the mean SOM expression landscape indicated by arrows. ( B ) Growth inhibition curves are shown for treatments of a patient-derived melanoma short-term culture using inhibitors directed against CDK2 (purvanolol), CDK4 palbociclib, activated BRAF (vemurafenib), ERK1/2 (SCH772984), and MEK1/2 (cobimetinib).

Article Snippet: The following small molecule inhibitors were used: CDK4 inhibitor palbociclib (PD-0332991, SEL-S1116-5MG, Biozol, Eching, Germany), CDK2 inhibitor purvanolol (SEL-S7793-5MG, Biozol), BRAF inhibitor vemurafenib (PLX4032, SEL-S1267-10MG, Biozol), MEK1/2 inhibitor cobimetinib (RG7420, SEL-S8041-5MG, Biozol), and ERK1/2 inhibitor SCH772984 (SEL-S7101-5MG, Biozol).

Techniques: Gene Expression, Expressing, Inhibition, Derivative Assay

(A) Experimental setup for steady-state RNA sequencing. (B) Numbers of up- or downregulated genes (log2-fold change >1) after 24 or 48 h HRAS G12V or KRAS G12V induction. (C) Numbers of unique and shared up-regulated genes after HRAS G12V or KRAS G12V induction. (D) Functional enrichment analysis (gene ontology, biological process) of genes downregulated 48 h after HRAS G12V or KRAS G12V induction. (E) Functional enrichment analysis (gene ontology, biological process) of genes upregulated 48 h after HRAS G12V or KRAS G12V induction. (G) Log2 fold-change in hallmark E2F target gene expression after HRAS G12V or KRAS G12V induction. (H) E2F1 expression (RNAseq, DEseq2) after HRAS G12V or KRAS G12V induction. N=3. (I) Log2 fold-change in hallmark MYC target gene expression after HRAS G12V or KRAS G12V induction. (J) MYC expression (RNAseq, DEseq2) after HRAS G12V or KRAS G12V induction. N=3. (K) Protein levels of pRB1 and α-TUBULIN after oncogene induction for the times indicated. (L) S phase percentage after HRAS G12V induction as determined by EdU labelling and flow cytometry. N=4. (M) S phase percentage after KRAS G12V induction. N=4. (N) S phase percentage after BRAF V600E induction. N=4. (O) Experimental setup for CDK4/6 inhibitor (CDK4/6i) treatment and release. (P) S phase percentage after HRAS G12V induction and treatment with CDK4/6i. N=2. (Q) Nuclear EU intensity after HRAS G12V induction and release from CDK4/6i. N=3. (R) Average replication fork speeds after HRAS G12V induction and release from CDK4/6i. N=3. Means +/-SEM (bars) are shown with 2-way ANOVA or mixed effects analysis.

Journal: bioRxiv

Article Title: PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress

doi: 10.64898/2026.03.16.711577

Figure Lengend Snippet: (A) Experimental setup for steady-state RNA sequencing. (B) Numbers of up- or downregulated genes (log2-fold change >1) after 24 or 48 h HRAS G12V or KRAS G12V induction. (C) Numbers of unique and shared up-regulated genes after HRAS G12V or KRAS G12V induction. (D) Functional enrichment analysis (gene ontology, biological process) of genes downregulated 48 h after HRAS G12V or KRAS G12V induction. (E) Functional enrichment analysis (gene ontology, biological process) of genes upregulated 48 h after HRAS G12V or KRAS G12V induction. (G) Log2 fold-change in hallmark E2F target gene expression after HRAS G12V or KRAS G12V induction. (H) E2F1 expression (RNAseq, DEseq2) after HRAS G12V or KRAS G12V induction. N=3. (I) Log2 fold-change in hallmark MYC target gene expression after HRAS G12V or KRAS G12V induction. (J) MYC expression (RNAseq, DEseq2) after HRAS G12V or KRAS G12V induction. N=3. (K) Protein levels of pRB1 and α-TUBULIN after oncogene induction for the times indicated. (L) S phase percentage after HRAS G12V induction as determined by EdU labelling and flow cytometry. N=4. (M) S phase percentage after KRAS G12V induction. N=4. (N) S phase percentage after BRAF V600E induction. N=4. (O) Experimental setup for CDK4/6 inhibitor (CDK4/6i) treatment and release. (P) S phase percentage after HRAS G12V induction and treatment with CDK4/6i. N=2. (Q) Nuclear EU intensity after HRAS G12V induction and release from CDK4/6i. N=3. (R) Average replication fork speeds after HRAS G12V induction and release from CDK4/6i. N=3. Means +/-SEM (bars) are shown with 2-way ANOVA or mixed effects analysis.

Article Snippet: Small molecule inhibitors and activators were sourced as follows: MEK inhibitor PD0325901 (1 μM) and CDK4/6 inhibitor Palbociclib (1 μM) were obtained from Merck Life Science UK Limited.

Techniques: RNA Sequencing, Functional Assay, Targeted Gene Expression, Expressing, RNA sequencing, Flow Cytometry